Wellcare Medicare Part D plans cover Zepbound only when it is prescribed for moderate to severe obstructive sleep apnea in adults with obesity, and only when the drug is on the member’s specific plan formulary and all plan requirements are met. Wellcare will not cover Zepbound when it is prescribed solely for weight loss. Members who want the drug for weight management have a separate route: the Medicare GLP-1 Bridge, a federal program that launched July 1, 2026, and provides eligible beneficiaries with Zepbound for a flat $50 monthly copay outside of their Part D plan.1Centers for Medicare & Medicaid Services. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
Why Weight-Loss Use Isn’t Covered
When Congress created Medicare Part D in 2003, it wrote in an exclusion barring coverage of drugs “used for anorexia, weight loss, or weight gain.”2National Center for Biotechnology Information. GLP-1 Receptor Agonists and Medicare Part D Coverage That statutory bar is still in place. CMS proposed reinterpreting it in late 2024 to allow coverage of anti-obesity drugs, but did not finalize the change in the Contract Year 2026 final rule released in April 2025.3Centers for Medicare & Medicaid Services. Contract Year 2026 Policy and Technical Changes Final Rule Fact Sheet So no Part D plan, Wellcare’s included, can cover Zepbound when the only purpose is losing weight.
When Wellcare Will Cover Zepbound
The exclusion is indication-specific. If a drug has an FDA-approved use outside the ban, Part D plans can cover it for that use. On December 20, 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, used alongside a reduced-calorie diet and increased physical activity.4U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea
Wellcare says Zepbound may be covered under its Part D plans when prescribed for OSA, provided the drug is on the member’s plan formulary and the plan’s coverage criteria are met.5Wellcare. Does Medicare Cover Weight Loss Drugs Those criteria often include prior authorization, step therapy, and quantity limits, and they vary by plan and state. Wellcare offers many different Part D and Medicare Advantage plans, and tier placement and cost-sharing for Zepbound are not uniform across them. Check your plan’s drug list, or call Wellcare, to see how your specific plan handles the drug.
Prior Authorization
If your plan requires prior authorization for Zepbound, your prescribing physician must send documentation showing medical necessity. According to Wellcare, this generally means the diagnosis, recent medical records such as sleep study results, and evidence of what has already been tried and why those options didn’t work or weren’t safe.6Wellcare. Does Medicare Cover Weight Loss Drugs
Wellcare does not publish one unified clinical criteria set across all its plans. For context on what Part D plans typically require, a UnitedHealthcare prior authorization form for Zepbound asks for a BMI of at least 30, a sleep study showing more than 15 respiratory events per hour, documented adherence to or unsuitability for CPAP therapy, at least one prior unsuccessful dietary weight-loss effort, no diabetes diagnosis, and a prescription from or in consultation with a sleep specialist, with the drug used alongside diet and exercise.7UnitedHealthcare. Prior Authorization Non-Formulary Zepbound Wellcare’s own criteria may differ.
What You Might Pay Through Part D
Zepbound’s wholesale acquisition cost runs from about $499 to $1,086 per fill, depending on dose.8Eli Lilly. Zepbound Pricing Information What you actually pay depends on tier placement in your Wellcare plan, the plan’s copay or coinsurance structure, and where you are in the Part D benefit phases. The $2,000 annual out-of-pocket cap on Part D spending, which took effect in 2025, limits total exposure, but a specialty-tier drug like Zepbound can push you to that cap quickly. Eli Lilly’s standard copay savings cards are not available to anyone enrolled in Medicare, Medicaid, or other government programs.9Eli Lilly. Zepbound Savings
The $50 Bridge for Weight-Loss Use
If you want Zepbound for weight loss rather than OSA, the main access path is the Medicare GLP-1 Bridge, a federal demonstration that began July 1, 2026, and runs through December 31, 2027.1Centers for Medicare & Medicaid Services. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries The Bridge covers Zepbound (KwikPen formulation), Wegovy (injections and tablets), and Foundayo at a flat $50 monthly copay.10Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
The program runs entirely outside Part D. Medicare administers it centrally, with Humana processing claims, and Part D plans like Wellcare do not need to opt in for their members to use it.11Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge If you have a Wellcare standalone Part D plan or a Wellcare Medicare Advantage plan with drug coverage, you can participate as long as you meet the clinical criteria. The $50 copay does not count toward your Part D deductible or the $2,000 out-of-pocket cap.
Eligibility and How to Enroll
There is no separate enrollment application. Your doctor submits the prior authorization request and prescription to the Bridge’s central processor, not to Wellcare.12Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge Information for Providers The provider has to attest that you meet one of these BMI-based thresholds:
- BMI 35 or higher, with no additional diagnosis required.
- BMI 30 or higher, with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher.
- BMI 27 or higher, with pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.
If you are already using Zepbound for an indication covered under standard Part D, such as OSA, you are not eligible for the Bridge and must keep getting the drug through your Part D plan.13Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge Information for Part D Plans
What Happens When the Bridge Ends
The Bridge is temporary. Its long-term successor is the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), scheduled to launch for Part D plans in January 2027.14Centers for Medicare & Medicaid Services. BALANCE Model Under BALANCE, CMS negotiates GLP-1 pricing with manufacturers directly, and participating Part D plans can cover drugs including Zepbound (KwikPen) for weight management. Manufacturers also fund a lifestyle support program for beneficiaries at no cost.
Participation is voluntary for plan sponsors. The application deadline was April 20, 2026, and as of the most recent public information it has not been confirmed whether Wellcare’s parent company, Centene, has signed on.15Centers for Medicare & Medicaid Services. BALANCE Part D Plans Request for Applications To keep access to Zepbound for weight loss after the Bridge expires, you’ll need a Part D plan that opted into BALANCE. For plans that do participate, out-of-pocket costs are capped at $50 per monthly supply for Enhanced Alternative plans and $125 per monthly supply for Basic Alternative or Actuarially Equivalent plans during the initial coverage phase.
If Wellcare Denies Your Request
Members can appeal when Wellcare denies coverage for Zepbound. The process has two stages.
The first step is a coverage determination, which is the plan’s initial decision on whether to cover the drug. If the drug isn’t on the formulary or requires prior authorization, your prescriber submits a request explaining medical necessity. Wellcare must issue a standard decision within 72 hours, or within 24 hours if your prescriber certifies that a delay could seriously harm your health.16Wellcare. Drug Coverage Determination Request
If that initial request is denied, you have 65 days from the denial notice to file an appeal, which Wellcare calls a redetermination. You can submit it by mail, fax, or phone. Standard appeal decisions come within seven calendar days. An expedited decision must be made within 72 hours when a prescriber confirms the delay could cause serious harm.17Wellcare. Drug Coverage Determination Appeal
A Note on Mounjaro
Mounjaro and Zepbound both contain tirzepatide, but they are sold under different brand names for different FDA-approved uses. Mounjaro is approved for type 2 diabetes and appears on Wellcare’s formulary with prior authorization required.18Wellcare. Wellcare 2026 Formulary Changes Zepbound is approved for chronic weight management and for OSA in adults with obesity. Under Part D, coverage follows the indication, not the molecule. A doctor could prescribe Mounjaro off-label for weight loss, but Part D plans aren’t obligated to cover off-label use that falls under the statutory exclusion, and in practice plans do not cover any GLP-1 for weight loss regardless of the brand name on the prescription.19HHS ASPE. Medicare Coverage of Anti-Obesity Medications